Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Ono seeks Japanese approval of Opdivo for relapsed or refractory Hodgkin's lymphoma

March 21, 2016

Mologen announces extension of TEACH study

March 17, 2016

Data presented on brentuximab vedotin in germ-cell tumors

March 17, 2016

DSMB recommends continuation of phase II trial of lirilumab in elderly patients with AML

March 16, 2016

Immunomedics terminates phase III PANCRIT-1 trial for clivatuzumab tetratexan

March 16, 2016

BioInvent and Oncurious partner with research consortium for phase I/IIa study of TB-403

March 15, 2016

FDA grants priority review to atezolizumab BLA for advanced bladder cancer

March 15, 2016

Medigene cleared to advance DC vaccine trial to phase II

March 14, 2016

Novartis submits sBLA for ofatumumab with fludarabine and cyclophosphamide for relapsed CLL

March 11, 2016

Genmab achieves new milestone in daratumumab collaboration with Janssen

March 10, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Case report links APOLD1 variant to vascular-type bleeding disorder
BioWorld Science
Vascular-type bleeding disorder (BDVAS) is a rare, autosomal dominant disorder mainly caused by impaired vascular integrity.
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...